oteseconazole 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
systemic antifungal agents, miconazole derivatives 5510 1340593-59-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • oteseconazole
  • vivijoa
  • VT-1161
Oteseconazole is an azole metalloenzyme inhibitor targeting the fungal sterol, 14alpha demethylase(CYP51), an enzyme that catalyzes an early step in the biosynthetic pathway of ergosterol, a sterol required for fungal cell membrane formation and integrity. Inhibition of CYP51 results in the accumulation of 14-methylated sterols, some of which are toxic to fungi. Through the inclusion of a tetrazole metal-binding group, oteseconazole has a lower affinity for human CYP enzymes.
  • Molecular weight: 527.40
  • Formula: C23H16F7N5O2
  • CLOGP: 4.97
  • LIPINSKI: 1
  • HAC: 7
  • HDO: 1
  • TPSA: 85.95
  • ALOGS: -5.06
  • ROTB: 9
  • Status: ONP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
April 26, 2022 FDA MYCOVIA PHARMACEUTICALS INC

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J02AC06 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIMYCOTICS FOR SYSTEMIC USE
ANTIMYCOTICS FOR SYSTEMIC USE
Triazole and tetrazole derivatives
FDA CS M0002083 Azoles
FDA EPC N0000175487 Azole Antifungal
FDA MoA N0000190113 Breast Cancer Resistance Protein Inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Recurrent vulvovaginal candidiasis (RVVC) indication 708126004
Lactation contraindication 63158009
Pregnancy, function contraindication 289908002




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
150MG VIVJOA MYCOVIA PHARMS N215888 April 26, 2022 RX CAPSULE ORAL 8754227 April 22, 2031 VIVJOA IS INDICATED TO REDUCE THE INCIDENCE OF RECURRENT VULVOVAGINAL CANDIDIASIS (RVVC) IN FEMALES WITH A HISTORY OF RVVC WHO ARE NOT OF REPRODUCTIVE POTENTIAL
150MG VIVJOA MYCOVIA PHARMS N215888 April 26, 2022 RX CAPSULE ORAL 11247981 May 9, 2033 VIVJOA IS INDICATED TO REDUCE THE INCIDENCE OF RECURRENT VULVOVAGINAL CANDIDIASIS (RVVC) IN FEMALES WITH A HISTORY OF RVVC WHO ARE NOT OF REPRODUCTIVE POTENTIAL

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
150MG VIVJOA MYCOVIA PHARMS N215888 April 26, 2022 RX CAPSULE ORAL April 26, 2027 NEW CHEMICAL ENTITY
150MG VIVJOA MYCOVIA PHARMS N215888 April 26, 2022 RX CAPSULE ORAL April 26, 2032 GENERATING ANTIBIOTIC INCENTIVES NOW

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Cytochrome P450 3A4 Enzyme INHIBITOR IC50 4.19 SCIENTIFIC LITERATURE
Cytochrome P450 2C9 Enzyme INHIBITOR IC50 4 SCIENTIFIC LITERATURE
Cytochrome P450 2C19 Enzyme INHIBITOR IC50 4.14 SCIENTIFIC LITERATURE
Lanosterol 14-alpha demethylase Enzyme INHIBITOR Kd 7.41 SCIENTIFIC LITERATURE DRUG LABEL

External reference:

IDSource
CHEBI:188153 CHEBI
VT1 PDB_CHEM_ID
CHEMBL3311228 ChEMBL_ID
C000599187 MESH_SUPPLEMENTAL_RECORD_UI
DB13055 DRUGBANK_ID
019048 NDDF
4041587 VANDF
C4519300 UMLSCUI
D11785 KEGG_DRUG
10138 INN_ID
77050711 PUBCHEM_CID
2602577 RXNORM
40649 MMSL
d09883 MMSL
VHH774W97N UNII

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
VIVJOA HUMAN PRESCRIPTION DRUG LABEL 1 74695-823 CAPSULE 150 mg ORAL NDA 32 sections